Strong Entyvio data boost confident Takeda

Recently-enlarged Japanese pharma giant Takeda Pharmaceutical (TYO: 4502) has presented data from the Phase III VISIBLE 2 trial at the European Crohn’s and Colitis Organisation (ECCO) in Vienna, Austria.

The study tests an investigational subcutaneous (SC) formulation of Entyvio (vedolizumab) for use during maintenance therapy in adults with moderately to severely active Crohn's disease (CD).

The results show that at week 52, significantly more patients in the test group were in clinical remission, 48%, compared with placebo, 34.3%, meeting the study’s primary endpoint.